Company news

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A (SSE:603456) news

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement…

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A (SSE:603456) news

Press releases & updates

(603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Resolutions of the 25th Meeting of the 8th Board of Directors

(603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes

(603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Amendments to the Articles of Association and Other Policies

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Notice on Convening the 3rd Extraordinary General Meeting in 2026

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Adjustment of Upper Limit of Repurchase Price Following Implementation of Dividend Distribution for the First Half of 2026

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Using Idle Raised Funds for Cash Management

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Repurchasing Shares for Cancellation and Reduction of Registered Capital and Notification to Creditors

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Redemption upon Maturity of Cash Management Products Purchased with Certain Idle Raised Funds

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Semi-annual Report for 2026

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Redemption upon Maturity of Cash Management Products Purchased with Idle Raised Funds and Continued Cash Management

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Completion of Closure of Certain Special Accounts for Raised Funds from 2020 Non-public Issuance of Shares

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Completion of Industrial and Commercial Change Registration

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Implementation of Canceling Partial Repurchased Shares

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction

"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital

Announcement on Progress in Wholly-owned Subsidiary Participating in Investment to Establish Jiaxing Longfeng Venture Capital Partnership (Limited Partnership)

Announcement on Obtaining Drug Registration Certificate by the Subsidiary

Announcement on Initially Repurchasing Shares through Call Auction and Progress in Repurchased Shares Reaching 1% of Total Share Capital

Announcement on Estimated Daily Related Party Transactions in 2026

Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Limit Concerning Shares Repurchase

Announcement on Implementation of Dividend Distribution for 2025

Announcement on the Company's Receipt of the Notice of Approval for Marketing Application of Chemical APIs

Announcement on Resolutions of the 21st Meeting of the 8th Board of Directors

Announcement on Notifying Creditors of Cancellation of Repurchased Shares

Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management

Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Application for Bank Credit with Self-owned Assets

Announcement on Receipt of a No-objection Letter from the Shanghai Stock Exchange for the Controlling Shareholder's Issuance of Exchangeable Corporate Bonds

Announcement on Obtaining the European CEP Certificate for Chemical Active Pharmaceutical Ingredient

Announcement on Obtaining Drug Registration Certificate by the Wholly-owned Subsidiary

Announcement on Progress in Opening a Special Settlement Account for Cash Management Products of Raised Funds and Using Temporary Idle Raised Funds for Cash Management

Announcement on Wholly-owned Subsidiary Certified as High-tech Enterprise

Announcement on Wholly-owned Subsidiary Participating in Investment to Establish Jiaxing Longfeng Venture Capital Partnership (Limited Partnership)

Announcement on Release of Pledge of Partial Shares of Controlling Shareholders

Announcement on Using Idle Raised Funds for Cash Management

Announcement on Approval of ANDA Number for Holding Subsidiary by the United States

Announcement on Resolutions of the 18th Meeting of the 8th Board of Directors

Indicative Announcement on Internal Restructuring of the Ownership Structure at the Level Above the Controlling Shareholder and Persons Acting in Concert, and Resulting Reduction in the Number of Actual Controllers

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Resolutions of the 17th Meeting of the 8th Board of Directors

Announcement on Convening the 2025 Q3 Performance Briefing

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

Announcement on Wholly-owned Subsidiary Completing Industrial and Commercial Change Registration

Announcement on Progress in Idle Raised Funds Used for Cash Management

Announcement on the Subsidiary Passing On-site Inspection by FDA

2025 Semi-annual Report

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on Completion of Industrial and Commercial Change Registration